Brigham and Wyss collaborate on Diagnostic Accelerator

Latest articles

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

Click the globe for translations.

Harvard’s Wyss Institute and Brigham and Women’s Hospital launch Diagnostic Accelerator which aims to create new diagnostic technologies through deep collaborations driven by unmet diagnostic needs.

Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Boston’s Brigham and Women Hospital announce their newly founded Diagnostic Accelerator (Brigham–Wyss DxA). By combining the institutions’ broad clinical and multi-disciplinary bioengineering expertise, it is hoped the Brigham–Wyss DxA will enable the fast creation of diagnostic technologies through deep collaborations in a process driven by previously unmet needs.

Longevity.Technology: The Brigham–Wyss DxA presents a new type of research collaboration with the potential to significantly compress the timeframe for introducing new diagnostic technologies specifically developed to solve high-value clinical problems. The collaborators plan to achieve this through a formal process by which unmet diagnostic challenges are identified by the Brigham clinical community, effectively matched with highly appropriate technologies created by the Wyss engineering community and the resulting diagnostic assays jointly validated and optimised in clinical settings.

Diagnostic testing at the Brigham will be performed under Clinical Laboratory Improvement Amendments (CLIA) conditions. This will ensure that the test results may be used by clinicians to evaluate how they can help inform their patients’ treatments, and result in better patient outcomes. Aggregated results will also be provided to the Wyss engineers in an iterative process to further inform the tests’ optimisation. CLIA regulation sets clinical standards for laboratory testing for diagnosis, prevention and treatment using human samples that align with its own evaluation and approval requirements.

Wyss
Diagnostics Accelerator_website listing image: The Brigham – Wyss DxA as a new type of research collaboration aims to dramatically shorten the timeframe for introducing new diagnostic technologies to address high-value clinical problems. Unmet diagnostic needs identified by Brigham clinicians, will be matched by appropriate technologies created by the Wyss Institute’s research and engineering community spanning a wide range of technology areas, and the resulting diagnostic tests jointly validated and optimized in clinical settings.

“Traditionally, the path for a new diagnostic technology has been long and inefficient, partly because cutting-edge technologies that in principle could address diagnostic needs are developed and commercialized as life sciences research tools,” said Dr David Walt, who is a Core Faculty member at the Wyss Institute and Professor of Pathology at the Brigham. “By founding an initiative that works on the principle of diagnostic pull rather than technology push, we hope to overcome the dearth of diagnostic capabilities for some of the most pressing disease areas here and around the world.”

“We’re thrilled to be collaborating with our colleagues at the Wyss on an endeavor that could significantly compress the timeline for introducing new diagnostics technologies,” said Dr Paul Anderson, MD, Senior Vice President of Research and Education at the Brigham. “One of the most significant aspects of this project is its potential impact on patient care — information provided by novel diagnostic tests could accelerate and guide the timely treatment of our patients.”

The Brigham–Wyss DxA uses an online portal to solicit proposals from clinical advocates for urgently needed diagnostic tests to improve clinical decision making and outcomes, including the required clinical specifications, such as form factor, clinical sensitivity and specificity. A Clinical Advisory Board comprised of both Harvard-affiliated and external clinicians and entrepreneurs will select the most promising ones. These will be responded to with a research effort at the Wyss DxA’s Biomarker Discovery Facility to identify the required biomarkers and analytical performance criteria to meet the diagnostic tests’ clinical specifications.

Biomarkers give detailed information about an individual’s health, signposting diseases, measuring aging and predicting outcomes, as well as giving a breakdown of biological, rather than chronological, age.

Wyss
BWH-Wyss-workflow: In a formalized process, Brigham clinicians identify unmet diagnostic needs that Wyss engineers will develop technology solutions and prototype assays for. These assays will be validated at the Brigham with patient samples under CLIA conditions, which align with the FDA’s own evaluation and approval requirements, and the results provided back to Wyss engineers in an iterative process that informs the tests’ optimization. Once the diagnostic assays meet all necessary requirements, their use in patient testing can be scaled. Wyss Institute at Harvard University

Wyss technology developers will then fit the clinical requirements and biomarker measurements with existing technologies or create new ones that can effectively address the diagnostic need. In the clinical testing phase, diagnostic tests and devices that pass the required rigorous criteria will then be validated in the Brigham Clinical Laboratory Diagnostic Accelerator under CLIA conditions, where Wyss staff will train Brigham clinical staff in their use.

“We believe that the Brigham–Wyss DxA can be a highly effective instrument to bring much needed diagnostic capabilities in a much shorter time-frame to patients in need and reduce often staggering medical costs from misdiagnosis,” said Dr Rushdy Ahmad, Senior Staff Scientist and Co-lead with David Walt of the Brigham–Wyss DxA.  Ahmad has strong biomarker discovery expertise and, along with Walt, coordinates activities related to the Brigham–Wyss DxA and other initiatives at the Wyss Institute. “As a new model, it has potential to attract the support from industry partners, philanthropic organizations, government and international agencies, non-governmental organizations, and additional collaborators,” he added.

“With this new cross-institutional, multi-disciplinary initiative we hope to bridge the almost ubiquitous diagnostic chasm between realistic clinical needs and innovative technology developers by creating the shortest distance path between these worlds that will bring novel diagnostic capabilities to patients faster than ever before. If successful, our model could set an example further reverberating within and far beyond the Harvard ecosystem,” said Wyss Founding Director Dr Donald Ingber, MD.

Images courtesy of Wyss Institute at Harvard University
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

At-home blood test powers personalised longevity advice

AgeRate develops proprietary DNA methylation clock and mobile app solution to offer users personalised longevity support. Canadian startup AgeRate is aiming to shake up the...

Researchers find warning signs for dementia in the blood

Levels of certain microRNAs indicate risk for cognitive decline. Researchers at the DZNE and the University Medical Center Göttingen (UMG) have identified molecules in the...

Staying young – from the cells up

Canadian scientists discover a new enzymatic complex that can stop cells from aging, opening the way to possible new therapies. Researchers at Université de Montréal...

Early and accelerated aging caused by cigarettes and alcohol

Epigenetic aging can start earlier than you think – and some of the usual suspects are in the frame. Aging and its associated health conditions...